BTAI Bioxcel Therapeutics Inc.
Filed as BIOXCEL THERAPEUTICS INC (COMMON STOCK), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab
In 2026 Q2 Howard Marks added to Bioxcel Therapeutics.
Who owns this now
Largest portfolio weights among holders, up to 0.0% (Howard Marks, Oaktree Capital Management). Not free-float ownership.
Who owns BTAI
Sorted by value, long equity only, as of 2026 Q2.
| History | |||||
|---|---|---|---|---|---|
| Howard Marks, Oaktree Capital Management | Add +472.3% | 1,380,248 | $1.9M | History |
Insider trades
Open-market buys and sales by BTAI's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- None no planned (10b5-1) sales
No open-market buys or sales on file.
Also filed in the last 12 months, not counted as buying or selling: 29 option exercises and 4 sales to cover taxes.
SEC filings
Recent issuer filings from EDGAR, 23 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 2.03,3.01 | Filing Doc | |
| 8-K | 1.01,1.03 | Filing Doc | |
| 8-K | 1.01,9.01 | Filing Doc | |
| 8-K | 1.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 1.01,9.01 | Filing Doc | |
| 8-K | 1.01,9.01 | Filing Doc | |
| 8-K | 1.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 3.02,9.01 | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| 424B5 | Filing Doc | ||
| 8-K | 1.01,9.01 | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 5.02,9.01 | Filing Doc | |
| 8-K | 8.01 | Filing Doc |
No filings match this filter.
Ownership over time
13Fs that reported it each quarter. Click a bar for that quarter’s holders.